Genfit S.A. (EPA:GNFT)

France flag France · Delayed Price · Currency is EUR
3.474
+0.198 (6.04%)
Jul 23, 2025, 5:35 PM CET
6.04%
Market Cap172.99M
Revenue (ttm)70.69M
Net Income (ttm)1.51M
Shares Out49.80M
EPS (ttm)0.03
PE Ratio115.80
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume311,724
Average Volume146,362
Open3.290
Previous Close3.276
Day's Range3.290 - 3.514
52-Week Range2.620 - 5.860
Beta1.27
RSI54.48
Earnings DateSep 22, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 180
Stock Exchange Euronext Paris
Ticker Symbol GNFT
Full Company Profile

Financial Performance

Financial Statements

News

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patie...

15 days ago - GlobeNewsWire

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of pati...

5 weeks ago - GlobeNewsWire

Genfit S.A. reports Q1 results

2 months ago - Seeking Alpha

GENFIT Reports First Quarter 2025 Financial Information

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the liv...

2 months ago - GlobeNewsWire

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 –  GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of pati...

2 months ago - GlobeNewsWire

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patien...

2 months ago - GlobeNewsWire

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); May 7, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patien...

2 months ago - GlobeNewsWire

GENFIT to Present Latest ACLF Research at EASL Congress 2025

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patien...

2 months ago - GlobeNewsWire

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of pat...

3 months ago - GlobeNewsWire

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of pat...

3 months ago - GlobeNewsWire

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

Lille, France; Cambridge, MA; Zurich, Switzerland; April 24, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare an...

3 months ago - GlobeNewsWire

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

3 months ago - Benzinga

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of pat...

4 months ago - GlobeNewsWire

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of pat...

4 months ago - GlobeNewsWire

GENFIT Announces Revenues and Cash Position as of December 31, 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 27, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...

5 months ago - GlobeNewsWire

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...

5 months ago - GlobeNewsWire

GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 14, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...

5 months ago - GlobeNewsWire

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 6, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of p...

5 months ago - GlobeNewsWire

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 30, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...

6 months ago - GlobeNewsWire

GENFIT Announces 2025 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...

6 months ago - GlobeNewsWire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the ...

6 months ago - GlobeNewsWire

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Read why GNFT stock's long-term prospects remain uncertain.

8 months ago - Seeking Alpha

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 13, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving th...

9 months ago - GlobeNewsWire

Genfit reports 9M results

9 months ago - Seeking Alpha